MTX, a positive drug in this study, could suppress dihydrofolate reductase and DNA synthesis, has proven to be a first-line anti-rheumatic agent, which inhibits the progression of RA mainly by inflammation control (Wang et al., 2018). The gene discussed is DHFR; the disease is rheumatoid arthritis.